GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » HTG Molecular Diagnostics Inc (STU:65H) » Definitions » Cyclically Adjusted Price-to-FCF

HTG Molecular Diagnostics (STU:65H) Cyclically Adjusted Price-to-FCF : (As of Jun. 08, 2024)


View and export this data going back to 2017. Start your Free Trial

What is HTG Molecular Diagnostics Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


HTG Molecular Diagnostics Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for HTG Molecular Diagnostics's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HTG Molecular Diagnostics Cyclically Adjusted Price-to-FCF Chart

HTG Molecular Diagnostics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

HTG Molecular Diagnostics Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of HTG Molecular Diagnostics's Cyclically Adjusted Price-to-FCF

For the Diagnostics & Research subindustry, HTG Molecular Diagnostics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HTG Molecular Diagnostics's Cyclically Adjusted Price-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, HTG Molecular Diagnostics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where HTG Molecular Diagnostics's Cyclically Adjusted Price-to-FCF falls into.



HTG Molecular Diagnostics Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

HTG Molecular Diagnostics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2023 is calculated as:

For example, HTG Molecular Diagnostics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2023 (Change)*Current CPI (Mar. 2023)
=-1.844/127.3478*127.3478
=-1.844

Current CPI (Mar. 2023) = 127.3478.

HTG Molecular Diagnostics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201212 0.000 96.871 0.000
201309 0.000 98.790 0.000
201312 -1,061.000 98.326 -1,374.165
201403 -1,414.000 99.695 -1,806.216
201406 -1,141.500 100.560 -1,445.587
201409 -1,480.500 100.428 -1,877.353
201412 -1,227.000 99.070 -1,577.230
201503 -118.838 99.621 -151.913
201506 -1,569.773 100.684 -1,985.493
201509 653.763 100.392 829.306
201512 -119.447 99.792 -152.430
201603 -149.895 100.470 -189.994
201606 -187.308 101.688 -234.573
201609 -105.513 101.861 -131.914
201612 -113.024 101.863 -141.302
201703 -99.909 102.862 -123.692
201706 -83.130 103.349 -102.434
201709 -59.344 104.136 -72.572
201712 -38.958 104.011 -47.699
201803 -18.701 105.290 -22.619
201806 -25.335 106.317 -30.347
201809 -19.639 106.507 -23.482
201812 -14.742 105.998 -17.711
201903 -31.704 107.251 -37.645
201906 -18.868 108.070 -22.234
201909 -23.511 108.329 -27.639
201912 -11.721 108.420 -13.767
202003 -9.975 108.902 -11.665
202006 -11.556 108.767 -13.530
202009 -9.408 109.815 -10.910
202012 -7.067 109.897 -8.189
202103 -7.435 111.754 -8.472
202106 -6.993 114.631 -7.769
202109 -6.260 115.734 -6.888
202112 -4.838 117.630 -5.238
202203 -8.085 121.301 -8.488
202206 -6.043 125.017 -6.156
202209 -5.048 125.227 -5.134
202212 -1.821 125.222 -1.852
202303 -1.844 127.348 -1.844

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


HTG Molecular Diagnostics  (STU:65H) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


HTG Molecular Diagnostics Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of HTG Molecular Diagnostics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


HTG Molecular Diagnostics (STU:65H) Business Description

Traded in Other Exchanges
Address
3430 E. Global Loop, Tucson, AZ, USA, 85706
HTG Molecular Diagnostics Inc is a commercial-stage RNA platform-based life sciences company focused on advancing the promise of precision medicine. Its proprietary NGS-adapted chemistry and HTG EdgeSeq platform automates sample processing and can quickly, robustly, and simultaneously profile hundreds or thousands of molecular targets using a relatively small amount of biological samples, in liquid or solid forms. Its products include instruments, consumables, and software that combine to form its HTG EdgeSeq platform. The company's menu of HTG EdgeSeq molecular profiling panels is automated on its HTG EdgeSeq platform, applying genomic sequencing tools to quickly generate gene expression data using its simplified workflow for customers.

HTG Molecular Diagnostics (STU:65H) Headlines

No Headlines